Drugs / Mitomycine C
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05200988 Background | Mar 2022 → Sep 2025 overdue | urinary bladder cancer, urothelial carcinoma | The Netherlands Cancer Institute | Active not recruiting | Met primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mitomycine C | “mitomycine C (day 1, 12 mg/m2, maximum dose of 20 mg)” NCT05200988 ↗ |